Form 4: Zeo ScientifiX CEO Granted 175,000 Restricted Shares

Zeo ScientifiX, Inc.'s CEO and CFO, Ian T. Bothwell, was granted 175,000 restricted common shares under the company's 2021 Equity Incentive Plan.

Summary

• Ian T. Bothwell, who serves as Director, 10% Owner, CEO, and CFO of Zeo ScientifiX, Inc. (ZEOX), received a grant of 175,000 restricted shares of common stock.
• The grant was made on January 14, 2026, under the company's 2021 Equity Incentive Plan.
• These restricted shares will vest in two tranches: 50% on the 8th month anniversary of the grant date and the remaining 50% on the 12th month anniversary.
• Following this transaction, Mr. Bothwell directly beneficially owns a total of 915,094 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of restricted shares to a key executive is generally a positive sign for aligning management incentives with shareholder interests, though it represents a form of dilution. The vesting schedule promotes long-term commitment.

Positives

• The grant of restricted shares aligns management's interests with shareholders through increased equity ownership, incentivizing long-term value creation.
• The structured vesting schedule encourages sustained commitment and performance from the CEO and CFO over the next 8 to 12 months.

Negatives

• The issuance of 175,000 new shares, even as a compensation grant, represents a potential dilutive effect on existing shareholders, although it is a common practice for executive incentives.

Future Outlook

The vesting schedule for the restricted shares indicates a future commitment from the CEO and CFO, with shares vesting over the next 8 to 12 months, aligning their incentives with the company's long-term performance and strategic objectives.

Industry Context

Equity grants are a standard component of executive compensation packages across various industries, designed to incentivize leadership and align their financial interests with the company's performance and shareholder value creation. This grant is consistent with typical practices for retaining and motivating key executives.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares, but also improved alignment of executive incentives with long-term shareholder value.
• Employees: May signal stability in leadership and a commitment to the company's long-term plans, potentially boosting morale and confidence.

Next Steps

• The first tranche of 50% of the restricted shares will vest on the 8th month anniversary of the grant date (approximately September 14, 2026).
• The second tranche of the remaining 50% of the restricted shares will vest on the 12th month anniversary of the grant date (approximately January 14, 2027).

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive as part of their compensation package. While it aligns management's interests with shareholders, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider this as a standard compensation event and continue to evaluate the company based on its broader financial reports and market conditions.

Keywords

Zeo ScientifiX, ZEOX, Ian T. Bothwell, Restricted Stock Grant, Equity Incentive Plan, CEO Compensation, Insider Ownership, Form 4, SEC Filing